Web Toolbar by Wibiya
Login | Sign Up AnonymousUser
twiter
New to Comunitee?


or Sign Up with Email

Business

>> ASTRAZENECA Latest News

23 HOURS AGO - Business Insider

A Must Read - Share

AstraZeneca to carve out antibiotic R&D into separate firm

By Ben HirschlerLONDON (Reuters) - Drugmaker AstraZeneca has decided to carve out its early-stage antibiotic research by creating a stand-alone subsidiary company, as it sharpens its focus on other therapy areas.Chief Executive Pascal Soriot said last year he was looking to partner or sell its anti-infective business, which is no longer viewed as a core area for the British drugmaker.AstraZeneca ...

Tags: AstraZeneca to carve out antibiotic R&D into separate firm,  Astrazeneca Latest News

FEB 26, 2015 - Boston Herald

A Must Read - Share

Heat blamed for spray vaccine's failure against swine flu

ATLANTA — The makers of the nasal spray version of the flu vaccine say now they know why it has failed to protect young U.S. children against swine flu — fragile doses got too warm.The AstraZeneca FluMist vaccine works well for most flu strains, but small studies found it didn't work very well against the swine flu bug that first ...

Tags: Heat blamed for spray vaccine's failure against swine flu,  Astrazeneca Latest News

FEB 23, 2015 - TheStreet

A Must Read - Share

Valeant Pharmaceuticals Buys Salix Pharmaceuticals in $14.5 Billion Megadeal

NEW YORK (The Deal) -- Laval, Canada-based Valeant Pharmaceuticals International announced on Sunday that it would acquire Salix Pharmaceuticals , of Raleigh, N.C., in a deal with an enterprise value of $14.5 billion, following last year's failed attempt to purchase Allergan . Under the terms of the deal Valeant will acquire all outstanding stock for $158 per share in cash in exchange ...

Tags: Valeant Pharmaceuticals Buys Salix Pharmaceuticals in $14.5 Billion Megadeal,  Astrazeneca Latest News

FEB 16, 2015 - Zacks Investment Research

A Must Read - Share

AstraZeneca's Patent for Pulmicort Respules Found Invalid - Analyst Blog

AstraZeneca (AZN) received disappointing news when the U.S. District Court said that the patent protecting Pulmicort Respules is invalid.

Tags: AstraZeneca's Patent for Pulmicort Respules Found Invalid - Analyst Blog,  Astrazeneca Latest News

FEB 12, 2015 - Investors Business Daily

A Must Read - Share

AstraZeneca sales outlook dims

Bernstein cut its forecast for sales of AstraZeneca's (AZN) key cholesterol drug Crestor 5% from consensus after it was bested by Pfizer's (PFE) Lipitor in a head-to-head study. Consensus for Crestor sales was $7.1 bil by 2015. Lipitor went off-patent in June, and generics are expected to flood the market starting in Nov. Tests showed patients on Crestor had less ...

Tags: AstraZeneca sales outlook dims,  Astrazeneca Latest News